Skip to main content

The nuclear medicine department of the Institut Jules Bordet offers patients diagnostic tests of the functional or molecular type, as well as treatments with targeted molecular radiotherapy.  

The diagnostic tests differ from those carried out in the Radiology Department in that they involve the intravenous administration of substances labelled with radioactive isotopes, which specifically make it possible to identify the functionality or characteristic of an organ or of the cancer.

Therapeutic applications in nuclear medicine (often called “molecular radiotherapy”) use the same type of substance (tracer) specifically targeting the cancer tissue, but this substance is labelled with radioactive isotopes which emit therapeutic particles of the beta or alpha type enabling the destruction of the diseased cells.

Research projects

Project 1

Somatostatin receptors imaging in relapsing and refractory multiple myeloma patients.

Project 2


Project 3

Molecular imaging of the tumor microenvironment

Project 4

Lutetium-177 dosimetry as a predictive biomarker of response in metastatic castrate resistant prostate cancer patients treated with psma radioligand therapy. the ludopath trial

    Project 5


    Project 6

    Etude pilote d’imagerie PSMA-PET/CT en vue d’explorer la possibilité d’une thérapie basée sur le PSMA comme future option thérapeutique chez les patientes atteintes d’un cancer du sein métastatique triple négatif.

    Project 7

    Evaluation préopératoire de la carcinomatose péritonéale par la moyen d’un FAPI-PET/CT.

    Our team

    Head of Department
    - Prof Patrick Flamen

    The team
    - Dr Géraldine Gebhart, H
    ead of Clinic
    - Dr Carlos ArtigasAssistant Head of Clinic
    Dr Ioannis KarfisAssistant Head of Clinic
    - Dr Elçin ÖzalpAssistant Head of Clinic
    - Dr Erwin WoffAssistant Head of Clinic
    - Dr Anne-Leen Deleu, Resident
    - Dr Isabel Marin Melero, Resident

    Radiophysicists (Department of Radiophysics)
    Bruno Vanderlinden, Radiophysicist
    Clémentine Marin, Radiophysicist 
    Gwennaëlle MarinRadiophysicist

    Physics control
    Marie Christiane Yimo-Wadje
    Théo Moschidis

    - Prof. 
    Zéna WimanaManager Radiopharmacy
    - Prof. Ghanem Ghanem
    - Adriana De Matos, Operator Radiopharmacy
    - Kadidja Ouldadda, Operator Radiopharmacy
    Sigrid Vercauteren, Radiopharmacist

    Coordination of radionuclide treatments
    - Marie-Noëlle Gheeraert
    - Pauwel Thijs

    Research Unit
    - Prof. Zéna Wimana, Radiopharmacy/pre-clinical imaging
    - Wendy Delbart, PhD Student/Research Assistant/ Biomedical Sciences, ULB
    Loubna Taraji Schiltz, Clinical Study Coordinator
    - Magdalena Mileva, MD, PhD Student/ Biomedical Sciences, ULB

    - Qaid Shagera, MD, PhD Student/ Biomedical Sciences, ULB
    - Ester Vicastillo Paredes, PhD Student/ Biomedical Sciences, ULB
    - Gabriela Critchi,
    Research Assistant

    - Sara Coelho, Head of Technologists

    - Jessie Toussaint
    - Anandi Henriet
    - Alyssa Hammouda (PET-scan/Isotopes)
    - Naïma Chadya (PET-scan/Isotopes)


     Scientific publications

    The role of PSMA radioligands in the diagnosis and treatment of prostate carcinoma.

    Authors : Rodríguez-Fraile M, Tamayo Alonso P, Rosales JJ, de Arcocha-Torres M, Caresia-Aróztegui AP, Cózar-Santiago MP, Orcajo-Rincon J, Simó Perdigó M, Delgado Bolton RC, Artigas C
    Year : 2022
    Journal : Rev Esp Med Nucl Imagen Mol (Engl Ed)
    Volume : 41
    Pages : 126-135

    An Atypical Behavior of Metastatic Lung Disease in a Young Woman With Osteosarcoma: A Case Report.

    Authors : Acquisto A, Duran Derijckere I, De Angelis R
    Year : 2022
    Journal : Cureus
    Volume : 14
    Pages : e21589

    Suspicious cold thyroid nodule with intense focal 68Ga-DOTATATE uptake: a case report.

    Authors : Manta R, Delbart W, Duran Derijckere I, Quiriny M, Demetter P, Flamen P, Karfis I
    Year : 2022
    Journal : Eur J Hybrid Imaging
    Volume : 6
    Pages : 8

    Author Correction: FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer.

    Authors : Gombos A, Venet D, Ameye L, Vuylsteke P, Neven P, Richard V, Duhoux FP, Laes JF, Rothe F, Sotiriou C, Paesmans M, Awada A, Guiot T, Flamen P, Piccart-Gebhart M, Ignatiadis M, Gebhart G
    Year : 2022
    Journal : NPJ Breast Cancer
    Volume : 8
    Pages : 38

    Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant.

    Authors : Malorni L, Tyekucheva S, Hilbers FS, Ignatiadis M, Neven P, Colleoni M, Henry S, Ballestrero A, Bonetti A, Jerusalem G, Papadimitriou K, Bernardo A, Seles E, Duhoux FP, Macpherson IR, Thomson A, Davies DM, Bergqvist M, Migliaccio I, Gebhart G, Zoppoli G, Bliss JM, Benelli M, McCartney A, Kammler R, De Swert H, Ruepp B, Fumagalli D, Maibach R, Cameron D, Loi S, Piccart-Gebhart M, Regan MM
    Year : 2022
    Journal : Eur J Cancer
    Volume : 164
    Pages : 39-51